JETEMA Co. Ltd (216080) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of JETEMA Co. Ltd stock KRW 1,657, price KRW 5,830, that is 71.6% below the price, quality 26 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 4,050 KRW – 19,975 KRW · fair‑value band 494.96 KRW – 2,819 KRW · the 5,830 KRW price screens above the 1,657 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow JETEMA Co. in your weekly email
Every Wednesday you see whether JETEMA Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices.
Show moreShow less
It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks.
JETEMA, Co., Ltd. was founded in 2009 and is headquartered in Wonju-si, South Korea.
Stock analysis
JETEMA Co. Ltd (216080) currently trades at 5,830 KRW, while our model-based Fair Value estimate is 1,657 KRW, 72% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the data coverage at low.
Scenario range: 494.96 KRW (bear) to 2,819 KRW (bull), the price of 5,830 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
JETEMA Co. Ltd reported revenue of 76.9B KRW in FY2025 versus 33.2B KRW in FY2021, a compound +23.3%/yr. Reported net income was −6.6B KRW in FY2025.
Key figures
Market cap 209B KRW (≈ $155M) Micro · P/S ratio 2.91 · EPS (TTM) −35.75 KRW · Net margin −1.7% · Return on equity −2.6% · Return on assets (EBIT) 0.5% (5-year average) · Operating margin 11.5% · Revenue (TTM) 76.6B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and 44% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −72%, 216080 screens richer than that median.
Fair Value models
Bear494.96 KRWFair Value 1,657 KRWBull2,819 KRW
Price 5,830 KRW · Downside -71.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.3%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−27.0% (2020) → 5.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 0/10 measures
Overall it trails its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside−71.6% · Bottom 25%
Profitability
Return on assets−3.2% · Bottom 25%
Net margin (12 months)−1.7% · Bottom 25%
Operating margin (12 months)11.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)−2.4% · Bottom 25%
Balance sheet
Debt / equity0.77× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B3.19× · Pricier than median
P/S (12 months)2.73× · Pricier than median
EV/EBITDA20.8× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)0· sector 40
PAST (return on equity)0· sector 30
HEALTH (low debt)62· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is JETEMA Co. Ltd (216080) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 1,657 KRW versus a price of 5,830 KRW, about 72% lower (overvalued).
What is the fair value of 216080?
Our model-based fair value for JETEMA Co. Ltd is 1,657 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 5,830 KRW.
What is the quality score of 216080?
JETEMA Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JETEMA Co. Ltd (216080)?
Our model-based price target is the fair value of 1,657 KRW (as of Nov 8, 2026) from 2 valuation models. Cautious scenario 494.96 KRW, optimistic scenario 2,819 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the JETEMA Co. Ltd stock forecast for 2026?
Our models put fair value at 1,657 KRW, about 72% lower versus a price of 5,830 KRW (overvalued). Cautious scenario 494.96 KRW, optimistic scenario 2,819 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of JETEMA Co. Ltd (216080)?
JETEMA Co. Ltd reported trailing-twelve-month revenue of about 76.6B KRW (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of JETEMA Co. Ltd (216080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JETEMA Co. Ltd it is 1,657 KRW per share (as of Nov 8, 2026), against a price of 5,830 KRW. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is JETEMA Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 216080 trades above its calculated fair value: price 5,830 KRW, fair value 1,657 KRW, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 216080?
No. The price is what the market pays today (5,830 KRW); the fair value is what the company's own numbers justify (1,657 KRW). For JETEMA Co. Ltd the two are 4,173 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is JETEMA Co. Ltd worth?
The market values JETEMA Co. Ltd at about 209B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 5,830 KRW; our models calculate a fair value of 1,657 KRW per share.
What do the bullish and bearish scenarios say about 216080?
Our models span a range for JETEMA Co. Ltd: cautious scenario 494.96 KRW, base 1,657 KRW, optimistic 2,819 KRW per share (as of Nov 8, 2026, price 5,830 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JETEMA Co. Ltd (216080)?
Balance-sheet figures for JETEMA Co. Ltd (as of Nov 8, 2026): return on equity −2.6%, debt of 0.77 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 216080 from its 52-week high?
JETEMA Co. Ltd trades at 5,830 KRW, about 46% below its 52-week high of 10,890 KRW and 44% above the low of 4,050 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,657 KRW is for.
Which stocks are comparable to JETEMA Co. Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JETEMA Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 5,830 KRW, calculated fair value 1,657 KRW (−72%), Quality Score 26/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 216080 calculated?
We run JETEMA Co. Ltd through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,657 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. JETEMA Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JETEMA Co. Ltd (216080)?
The closing price on Nov 6, 2026 was 5,830 KRW. Our model-based fair value is 1,657 KRW, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JETEMA Co. Ltd right now?
The price sits above even our optimistic bull case (2,819 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (494.96 KRW to 2,819 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of JETEMA Co. Ltd
How large is the market capitalisation of JETEMA Co. Ltd (216080)?
The market capitalisation of JETEMA Co. Ltd is 209B KRW (≈ $155M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JETEMA Co. Ltd (216080)?
The price-to-sales ratio of JETEMA Co. Ltd is 2.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of JETEMA Co. Ltd (216080)?
Earnings per share at JETEMA Co. Ltd are −35.75 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of JETEMA Co. Ltd (216080)?
The net margin of JETEMA Co. Ltd is −1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JETEMA Co. Ltd (216080)?
The return on equity (ROE) of JETEMA Co. Ltd is −2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JETEMA Co. Ltd (216080)?
On an EBIT basis the return on assets of JETEMA Co. Ltd is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JETEMA Co. Ltd (216080)?
The operating margin of JETEMA Co. Ltd is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JETEMA Co. Ltd (216080)?
Revenue at JETEMA Co. Ltd is growing −2.4% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JETEMA Co. Ltd (216080)?
Earnings per share at JETEMA Co. Ltd are growing −39.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does JETEMA Co. Ltd (216080) generate?
The free cash flow of JETEMA Co. Ltd is −4.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does JETEMA Co. Ltd (216080) carry?
The net debt of JETEMA Co. Ltd is 112B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch JETEMA Co. Ltd in the live analysis
One click puts JETEMA Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026